- Trial phase
- Phase 2-ready (Phase 1 completed)
- Time to market
- ACR-525 is Phase 2-ready but has not yet initiated a Phase 2 trial. Assuming successful development, an approval in EoE would likely be several years away (3-5+ years minimum).
- Why 3/10
- No hard dated binary catalyst (PDUFA or pivotal readout) is scheduled for ACR-525 in the next ~12 months. The asset was just acquired on November 6, 2026, and is Phase 2-ready but has not yet initiated a Phase 2 trial. The next catalysts are a KOL webcast (Nov 10) and Q3 earnings (Nov 12), neither of which is a binary regulatory or pivotal-data event for this drug.
Watch the November 10 KOL webcast for clinical development strategy and the November 12 Q3 earnings call for cash position updates. The undisclosed acquisition cost makes it hard to assess the financial impact on Acrivon's ~$75M market cap company. Any subsequent financing or partnership announcement would be a key signal.
Price Chart
Executive Summary
ACR-525 is a Phase 2-ready, oral, highly selective JAK1 inhibitor that Acrivon Therapeutics (NASDAQ: ACRV) acquired from Aqilion AB on November 6, 2026, for an undisclosed cash sum with no future milestone or royalty obligations. Formerly known as AQ280, the drug targets eosinophilic esophagitis (EoE) as its first potential indication and marks Acrivon's expansion from precision oncology into immunology and inflammation. The deal closed concurrently with signing and was approved by both companies' boards. Acrivon plans to host a KOL webcast on November 10 to discuss the development plan. At a ~$75M market cap and ~$1.60 stock price, the undisclosed deal cost and early-stage nature of the asset make this a neutral watch item with no near-term binary catalyst.
How It Works
ACR-525 is an oral JAK1 inhibitor. JAK1 is an enzyme that helps transmit inflammatory signals inside cells. By blocking JAK1, the drug aims to reduce the inflammation that drives autoimmune diseases. It is designed to be highly selective for JAK1 over other similar enzymes (JAK2, JAK3, TYK2), which may reduce side effects like anemia or immune suppression that broader JAK inhibitors can cause.
Trial Status
ACR-525 (formerly AQ280) has completed Phase 1 studies and is described as Phase 2-ready. The first targeted indication is eosinophilic esophagitis (EoE), using a formulation designed for patients with difficulty swallowing. No Phase 2 trial has been initiated or registered as of the acquisition date (November 6, 2026).
The Two-Sided Case
Upcoming Catalysts
- November 10, 2026: KOL webcast on ACR-525 development plan and EoE clinical strategy
- November 12, 2026: ACRV Q3 2026 earnings call (company-level catalyst)
- Initiation of Phase 2 trial in EoE (date not yet announced)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Acrivon Therapeutics, Inc. 8-K ACRV ·Originating report